race oncology looks to accelerate clinical development of bisantrene
Published 5 months ago • 993 plays • Length 6:42Download video MP4
Download video MP3
Similar videos
-
8:00
race oncology highlights impressive bisantrene clinical data
-
4:36
race oncology partners with george clinical for rc220 bisantrene trials
-
5:15
race oncology completes glp studies for rc220 bisantrene; closer to human trials
-
6:49
race oncology receives positive results from aml trial of bisantrene
-
5:19
cramer: this biotech stock could be worth over $100 billion on an fda approval
-
10:46
pitt st research interview with race oncology's ceo phil lynch and cso dr daniel tillett
-
22:42
race oncology raises $29.7m to fund development of lead anti-cancer drug zantrene
-
5:10
race oncology receives fda orphan drug designation extension for bisantrene rc220
-
3:50
race oncology expands vision beyond cancer with new drug discovery program
-
3:39
executive interview - race oncology
-
0:49
race oncology reports bisantrene shows potent anti-cancer activity
-
0:36
race trials new zantrene drug for extramedullary acute myeloid leukaemia (emd aml) – animation
-
32:00
race oncology (asx: rac) day 2 of the ird invest 2021 conference.
-
11:26
race oncology's daniel tillett details positive preclinical results for bisantrene in breast cancer
-
6:42
race oncology (asx: rac) reveals breakthrough chemotherapy heart protection discovery for zantrene®
-
40:10
an inquiry into fto and bisantrene: race oncology (asx:rac)
-
8:05
race oncology receives us fda rare paediatric disease designation for aml treatment
-
33:20
sharewise webinar with race oncology ceo daniel tillett
-
19:11
sharecafe 'hidden gems' webinar - race oncology asx:rac
-
7:30
race oncology kicks off safety studies for rc220